King's College London

Research portal

TRPC5 and the path towards analgesic drug development

Research output: Contribution to journalShort surveypeer-review

Original languageEnglish
Pages (from-to)687-688
Number of pages2
JournalTrends in Neurosciences
Volume44
Issue number9
DOIs
Accepted/In press2021
PublishedSep 2021

Bibliographical note

Funding Information: F.D. has received funding through an MRC New Investigator Research Grant ( MR/P010814/1 ) and a Medical Research Foundation Prize ( MRF-160-0015-ELP-DENK-C0844 ). She thanks Dr David Andersson for his insightful comments on this manuscript. Funding Information: F.D. has received funding through an MRC New Investigator Research Grant (MR/P010814/1) and a Medical Research Foundation Prize (MRF-160-0015-ELP-DENK-C0844). She thanks Dr David Andersson for his insightful comments on this manuscript. F.D. is on the Scientific Advisory Board of the Swedish pharmaceutical company Cellectricon. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Documents

  • TINS_spotlight_v5

    TINS_spotlight_v5.docx, 53.5 KB, application/vnd.openxmlformats-officedocument.wordprocessingml.document

    Uploaded date:04 Aug 2021

    Version:Submitted manuscript

King's Authors

Abstract

A recent study by Sadler et al. highlights transient receptor potential canonical 5 (TRPC5) as a potential target for treating pain conditions. This article discusses their findings in the context of analgesic drug development, an urgent pursuit required to combat the opioid crisis and help millions of people with chronic pain.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454